검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cediranib |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Non-Small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets in the VEGF and PI3K pathway |
MoA Biomarker | biomarkers to target potential treatments |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis.. Glioblastoma (GBM) is the most aggressive primary brain tumor with a poor prognosis. The current standard regimen of surgery combined with concurrent temozolomide chemoradiotherapy has limited efficacy. Multiple targeted therapies have been evaluated in randomized controlled trials (RCTs), b… |
Clinical Primary efficacy | ORR 15% |
Clinical ORR | 15% |
Clinical Result source | ClinicalTrials.gov NCT00227760 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cediranib |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Non-Small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets in the VEGF and PI3K pathway |
MoA Biomarker | biomarkers to target potential treatments |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis.. Glioblastoma (GBM) is the most aggressive primary brain tumor with a poor prognosis. The current standard regimen of surgery combined with concurrent temozolomide chemoradiotherapy has limited efficacy. Multiple targeted therapies have been evaluated in randomized controlled trials (RCTs), b… |
Clinical Primary efficacy | ORR 15% |
Clinical ORR | 15% |
Clinical Result source | ClinicalTrials.gov NCT00227760 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교